Guggenheim Cuts GeneDx (NASDAQ:WGS) Price Target to $70.00

Key Points

• Guggenheim cut its price target on GeneDx from $100 to $70 while keeping a "buy" rating, implying only about a 3.05% upside from the stock's current level.
• Q1 results disappointed: GAAP EPS of -$0.28 missed the -$0.06 expectation and revenue of $102.25M trailed estimates, and management guided FY revenue to roughly $475–$490M versus street ~ $549M, highlighting margin and cash‑flow pressure.
• Insider activity is mixed: director Keith A. Meister bought 140,026 shares (~$11.37M) raising his stake, while other insiders have sold recently; institutional investors own about 61.7% of the company.

GeneDx (NASDAQ:WGS - Get Free Report) had its price objective decreased by research analysts at Guggenheim from $100.00 to $70.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price objective suggests a potential upside of 3.05% from the company's current price.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of GeneDx from a "buy" rating to a "hold" rating in a report on Sunday, February 8th. Piper Sandler reissued an "overweight" rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Weiss Ratings reissued a "sell (d)" rating on shares of GeneDx in a report on Wednesday, January 21st. Canaccord Genuity Group set a $100.00 target price on shares of GeneDx and gave the stock a "buy" rating in a report on Monday, April 20th. Finally, Zacks Research cut shares of GeneDx from a "strong-buy" rating to a "hold" rating in a report on Friday, April 24th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $98.33.

GeneDx Trading Up 3.9%

NASDAQ WGS opened at $67.93 on Tuesday. The company has a fifty day simple moving average of $71.45 and a two-hundred day simple moving average of $107.17. The stock has a market cap of $1.99 billion, a P/E ratio of -90.57 and a beta of 2.06. GeneDx has a 12-month low of $55.17 and a 12-month high of $170.87. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to analysts' expectations of $112.46 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.During the same period in the prior year, the business posted ($0.23) EPS. On average, analysts forecast that GeneDx will post 0.75 earnings per share for the current year.

Insider Activity at GeneDx

In related news, Director Keith A. Meister bought 140,026 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were acquired at an average price of $81.19 per share, for a total transaction of $11,368,710.94. Following the completion of the transaction, the director directly owned 3,228,150 shares in the company, valued at $262,093,498.50. This trade represents a 4.53% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Bryan Dechairo sold 5,961 shares of GeneDx stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total transaction of $510,857.70. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 109,989 shares of company stock worth $7,888,023 in the last ninety days. 29.60% of the stock is owned by company insiders.

Institutional Trading of GeneDx

Several institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC acquired a new position in GeneDx during the third quarter worth about $48,157,000. Principal Financial Group Inc. boosted its position in GeneDx by 340.4% during the third quarter. Principal Financial Group Inc. now owns 59,624 shares of the company's stock worth $6,424,000 after acquiring an additional 46,085 shares during the last quarter. Impax Asset Management Group plc acquired a new position in GeneDx during the third quarter worth about $5,387,000. Sumitomo Mitsui Trust Group Inc. boosted its position in GeneDx by 30.6% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 381,725 shares of the company's stock worth $49,647,000 after acquiring an additional 89,470 shares during the last quarter. Finally, Telemark Asset Management LLC acquired a new position in GeneDx during the third quarter worth about $12,929,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Strong underlying volume growth: management reported 34% year‑over‑year volume growth in exome and genome testing, supporting longer‑term demand for the core business. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Neutral Sentiment: Revenue and gross profit were higher year‑over‑year ($102.3M revenue; gross profit up ≈17%), indicating growth despite near‑term margin pressure. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Conference call materials and transcript are available for more detail on drivers and cadence of margin recovery; listeners can assess management commentary for guidance color. GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed materially: GAAP loss per share of ($0.28) vs. consensus loss of ($0.06), with revenue below estimates (~$102.25M vs. ~$112–114M est.), a primary catalyst for downward pressure. GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Full‑year revenue guidance markedly below consensus: management set FY revenue of roughly $475–$490M vs. street ~$549M, increasing downside risk to near‑term estimates and valuation. GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
• Negative Sentiment: Profitability and cash flow stress: the quarter showed a large operating and net loss and meaningful operating cash outflow, which raises execution and financing concerns until margins and cash generation improve. GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
• Negative Sentiment: Insider selling: recent disclosure shows the CFO sold shares (~$25.6k reported) and several insiders have sold shares in recent months, which markets often view as a negative signal. Insider Selling: GeneDx NASDAQ: WGS CFO Sells $25,554.48 in Stock

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.